Profitability Ratios
| Ratio |
Value |
| GP Margin |
31.7% |
| EBIT Margin |
-336.9% |
| EBITDA Margin |
-21.4% |
| Operating Margin |
-348.5% |
| Pretax Margin |
-341.3% |
| Cont. Ops Margin |
-341.5% |
| Net Margin |
-341.5% |
| Bottom Line Margin |
-341.5% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
6.89 |
| Quick Ratio |
5.99 |
| Solvency Ratio |
-0.053 |
| Cash Ratio |
1.17 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
|
| PEG Ratio |
-0.02 |
| Forward PEG |
-0.02 |
| Price/Book |
104.87 |
| Price/Sales |
3.51 |
| Price/FCF |
-4.92 |
| Price/Op Cash Flow |
-5.04 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.9686 |
| Debt/Equity |
141.9821 |
| Debt/Capital |
0.9930 |
| Long-Term Debt/Capital |
0.9924 |
| Financial Leverage |
146.58 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
0.43 |
| Operating Cash Flow Ratio |
-2.044 |
| Operating Cash Flow/Sales |
-69.5% |
| Free Cash Flow/Operating Cash Flow |
102.4% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
-4.66 |
| Interest Coverage |
-80.1785 |
| Short-Term Operating Cash Flow Coverage |
-248.23 |
| Operating Cash Flow Coverage |
-0.15 |
| Capital Expenditure Coverage |
-40.98 |
| Dividend + Capital Expenditure Coverage |
-40.98 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
0.0000% |
| Dividend Yield |
0.0000% |
| Dividend Yield % |
0.0000% |
| Dividend Per Share |
0.0000 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
0.53 |
| EPS |
-1.822 |
| Debt/Share |
2.5551 |
| Cash/Share |
0.93 |
| Book Value/Share |
0.02 |
| Tangible BV/Share |
-1.09 |
| Equity/Share |
0.02 |
| Operating Cash Flow/Share |
-0.371 |
| Capital Expenditure/Share |
0.009 |
| FCF/Share |
-0.380 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
1.001 |
| Earnings Before Tax/EBIT |
0.979 |
| Price/Fair Value |
104.87 |
| Debt/Market Cap |
1.2531 |
| Effective Tax Rate |
-0.1% |
| Enterprise Value Multiple |
-36.75 |
PACB - Pacific Biosciences of California, Inc.